Daejeon, South Korea

Suho Park

USPTO Granted Patents = 6 

Average Co-Inventor Count = 15.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Suho Park: Innovator in Antibody-Drug Conjugates

Introduction

Suho Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 6 patents, his work has the potential to impact therapeutic approaches in various medical applications.

Latest Patents

Among his latest patents, Suho Park has developed compounds and compositions comprising substituted benzodiazepines as antibody-drug conjugates. This innovation provides a new avenue for therapeutic interventions. Additionally, he has worked on antibody-drug conjugates that incorporate anti-B7-H3 antibodies. These conjugates feature active agents linked to the antibody through a specialized linker, enhancing their efficacy in targeting specific antigens. His research also includes monoclonal antibodies and their variants, which are crucial for therapeutic, diagnostic, and prophylactic applications.

Career Highlights

Suho Park has been associated with notable companies such as Intocell, Inc. and Y-Biologics Inc. His work in these organizations has allowed him to advance his research and contribute to the development of innovative medical solutions. His expertise in antibody-drug conjugates positions him as a key figure in the field.

Collaborations

Suho Park has collaborated with talented individuals in his field, including Taekyo Park and Sung Ho Woo. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Suho Park's contributions to the field of biochemistry, particularly in antibody-drug conjugates, highlight his innovative spirit and dedication to advancing medical science. His patents and collaborations reflect a commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…